Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| Line 28: | Line 28: | ||
|- | |- | ||
|} | |} | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 50%; text-align:center;" |
| − | !style="width: | + | !style="width: 25%"|Study |
| − | !style="width: | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928-untreated)] | ||
| Line 57: | Line 57: | ||
|- | |- | ||
|} | |} | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 50%; text-align:center;" |
| − | !style="width: | + | !style="width: 25%"|Study |
| − | !style="width: | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928-treated)] | ||
Revision as of 01:08, 10 May 2019
| Section editor | |
|---|---|
 |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN Twitter: TravisOsterman |
Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, first-line
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Planchard et al. 2017 (BRF113928-untreated) | Phase II |
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed
Advanced or metastatic disease, previously treated, BRAF inhibitor-naive
Dabrafenib & Trametinib
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Planchard et al. 2016 (BRF113928-treated) | Phase II |
All enrolled patients had BRAF p.V600E mutations and had progressed on 1 to 3 prior regimens.
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to PMC article PubMed